A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Phase 2
180
about 2.4 years
18+
38 sites in AZ, CA, CO +11
About this study
Researchers are testing different treatments for moderately to severely active rheumatoid arthritis. The trial will evaluate the efficacy and safety of lutikizumab, ravagalimab, or a combination of both compared to placebo. Participants will attend regular visits during it at a hospital or clinic.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lutikizumab
- 2.Take Placebo
- 3.Take Ravagalimab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Primary: Number of Participants with Adverse Events (AEs)
Secondary: Change from Baseline in DAS28 (CRP), Percentage Of Participants Achieving CR per CDAI, Percentage Of Participants Achieving Clinical Remission (CR) per DAS28 (CRP), Percentage Of Participants Achieving Low Disease Activity (LDA) per Disease Activity Score-28 With C-Reactive Protein (DAS28-CRP)
Immune